Cyberounds Logo
August 11, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Pulmonary Embolism: 2019 Update
Christopher Kabrhel, M.D.

Dr. Kabrhel is Associate Professor of Surgery, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Updated by Keith Albrektson, M.D., Ben Alencherry, M.D., and Jihane Faress, M.D.

Dr. Albrektson is Resident, Dr. Alencherry is Chief Resident, and Dr. Faress is Assistant Professor, Department of Medicine, University Hospitals Cleveland Medical Center, Louis Stokes Cleveland VA Medical Center and Case Western Reserve University.

Within the past 12 months, Dr. Albrektson, Alencherry and Faress report no commercial conflicts of interest. Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose relevant to this activity.

Release Date: 04/15/2019
Termination Date: 04/15/2022
Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe how risk factors, signs and symptoms can be used to determine the pretest probability of pulmonary embolism;
  • Discuss the characteristics of the most commonly used tests for pulmonary embolism;
  • Describe the different methods to risk stratify patients with pulmonary embolism and understand the importance of risk stratification;
  • Discuss the indications for low-molecular weight-heparin therapy and thrombolysis.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity